Cargando…

Role of brentuximab vedotin in the treatment of relapsed or refractory Hodgkin lymphoma

Brentuximab vedotin (BV) is an antibody-drug conjugate that targets CD30-positive malignancies via an anti-CD30 monoclonal antibody linked to monomethyl auristatin E, a microtubule-disrupting agent, by a protease-cleavable linker. BV has received accelerated approval from the US Food and Drug Admini...

Descripción completa

Detalles Bibliográficos
Autores principales:	Siddiqi, Tanya, Thomas, Sandra H, Chen, Robert
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2014
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3959807/ https://www.ncbi.nlm.nih.gov/pubmed/24672256 http://dx.doi.org/10.2147/PGPM.S57700

Ejemplares similares

Brentuximab vedotin for relapsed or refractory Hodgkin’s lymphoma
por: Chen, Runzhe, et al.
Publicado: (2015)

Brentuximab vedotin for relapsed or refractory Hodgkin lymphoma: experience in Turkey
por: Salihoglu, A., et al.
Publicado: (2014)

Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma. The Hellenic experience
por: Angelopoulou, Maria K., et al.
Publicado: (2017)

Emerging Pharmacotherapy for Relapsed or Refractory Hodgkin’s Lymphoma: Focus on Brentuximab Vedotin
por: Furtado, Michelle, et al.
Publicado: (2012)

Brentuximab Vedotin Treatment for Primary Refractory Hodgkin Lymphoma
por: Wu, Hung-Bo, et al.
Publicado: (2013)

A Chinese patient with relapsed and refractory Hodgkin lymphoma treated with brentuximab vedotin
por: Cao, Zhi-Gang, et al.
Publicado: (2013)

Combination brentuximab vedotin and bendamustine for pediatric patients with relapsed/refractory Hodgkin lymphoma
por: Forlenza, Christopher J., et al.
Publicado: (2021)

The Evolving Role of Brentuximab Vedotin in Classical Hodgkin Lymphoma
por: Lai, Catherine, et al.
Publicado: (2019)

Efficacy of Brentuximab Vedotin and Nivolumab in Refractory or Relapsed Hodgkin Lymphoma: A Systematic Review
por: Macapagal, Sharina C, et al.
Publicado: (2022)

Brentuximab vedotin after autologous transplantation in pediatric patients with relapsed/refractory Hodgkin lymphoma
por: Forlenza, Christopher J., et al.
Publicado: (2023)

Brentuximab vedotin for the treatment of patients with relapsed or refractory Hodgkin lymphoma after autologous stem cell transplantation
por: Kaloyannidis, Panayotis, et al.
Publicado: (2019)

Quality-of-life analysis of pembrolizumab vs brentuximab vedotin for relapsed/refractory classical Hodgkin lymphoma
por: Zinzani, Pier Luigi, et al.
Publicado: (2022)

P111: Phase I Trial of Brentuximab Vedotin plus Cyclosporine in Relapsed/Refractory Hodgkin Lymphoma
por: Kambhampati, Swetha, et al.
Publicado: (2022)

Safety and Efficacy of Brentuximab Vedotin in the Treatment of Classic Hodgkin Lymphoma
por: Makita, Shinichi, et al.
Publicado: (2020)

P112: Phase II Trial of Brentuximab Vedotin plus ibrutinib in Relapsed/Refractory Hodgkin Lymphoma
por: Mei, Matthew, et al.
Publicado: (2022)

Brentuximab Vedotin in Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma
por: Tsang, Vivian
Publicado: (2012)

Brentuximab vedotin for relapsed or refractory CD30+ Hodgkin lymphoma: a multicenter analysis from Asia
por: Yang, Qing-Ming, et al.
Publicado: (2014)

Prolonged Remission by Pembrolizumab and Brentuximab-Vedotin Combination Therapy in Heavily-Pretreated Relapsed/Refractory Hodgkin’s Lymphoma
por: Yu, Tsung-Ying, et al.
Publicado: (2020)

Hematopoietic Stem Cell Transplantation and Brentuximab Vedotin for Patients with Relapsed or Refractory Hodgkin Lymphoma and Systemic Anaplastic Large-Cell Lymphoma
por: Ishizawa, Kenichi, et al.
Publicado: (2019)

Chemoimmunotherapy with brentuximab vedotin combined with ifosfamide, gemcitabine, and vinorelbine is highly active in relapsed or refractory classical Hodgkin lymphoma
por: Abuelgasim, Khadega A., et al.
Publicado: (2019)

Brentuximab Vedotin and Pembrolizumab Combination in Patients with Relapsed/Refractory Hodgkin Lymphoma: A Single-Centre Retrospective Analysis
por: Massaro, Fulvio, et al.
Publicado: (2022)

Desensitization of Brentuximab Vedotin in a Patient with Hodgkin Lymphoma
por: Khalid, Sidra, et al.
Publicado: (2018)

Brentuximab vedotin in Hodgkin lymphoma and anaplastic large-cell lymphoma: an evidence-based review
por: Donato, Eva M, et al.
Publicado: (2018)

Acute Pancreatitis Following Brentuximab Vedotin Therapy for Refractory Hodgkin Lymphoma: A Case Report
por: Urru, S. A. M., et al.
Publicado: (2014)

Brentuximab Vedotin in CD30+ Lymphomas
por: Perini, Guilherme Fleury, et al.
Publicado: (2013)

Italian real life experience with brentuximab vedotin: results of a large observational study on 234 relapsed/refractory Hodgkin’s lymphoma
por: Pellegrini, Cinzia, et al.
Publicado: (2017)

Efficacy and safety of nivolumab combined with brentuximab vedotin after nivolumab monotherapy failure in patients with relapsed and refractory classic Hodgkin lymphoma
por: Fedorova, Liudmila V., et al.
Publicado: (2021)

Targeted therapy for Hodgkin lymphoma and systemic anaplastic large cell lymphoma: focus on brentuximab vedotin
por: Chen, Xueyan, et al.
Publicado: (2013)

Patient-reported outcomes of brentuximab vedotin in Hodgkin lymphoma and anaplastic large-cell lymphoma
por: Chen, Robert, et al.
Publicado: (2016)

Brentuximab Vedotin: A Review in CD30-Positive Hodgkin Lymphoma
por: Scott, Lesley J.
Publicado: (2017)

Hodgkin Lymphoma on Hemodialysis Successfully Treated with Extended Courses of Brentuximab Vedotin
por: Uchimura, Ayana, et al.
Publicado: (2022)

Response to Brentuximab Vedotin by CD30 Expression in Non-Hodgkin Lymphoma
por: Jagadeesh, Deepa, et al.
Publicado: (2022)

Treatment patterns and costs of care for patients with relapsed and refractory Hodgkin lymphoma treated with brentuximab vedotin in the United States: A retrospective cohort study
por: Szabo, Shelagh M., et al.
Publicado: (2017)

Brentuximab vedotin in the treatment of elderly Hodgkin lymphoma patients at first relapse or with primary refractory disease: a phase II study of FIL ONLUS
por: Stefoni, Vittorio, et al.
Publicado: (2020)

Promising remissions in relapsed refractory classical Hodgkin lymphoma patients requiring multiple salvage regimens before transplantation in the brentuximab vedotin era
por: Abuelgasim, Khadega A, et al.
Publicado: (2021)

P104: Consolidation Therapy with Brentuximab Vedotin after Autologous Stem Cell Transplantation for Relapsed/Refractory Hodgkin Lymphoma in the Czech Republic.
por: Michalka, Jozef, et al.
Publicado: (2022)

BRENTUXIMAB VEDOTIN AND BENDAMUSTINE (BvB) IN PATIENTS WITH RELAPSED OR REFRACTORY HODGKIN LYMPHOMA: AN INTERNATIONAL, MULTICENTER, SINGLE-ARM, PHASE 1–2 TRIAL
por: O’Connor, Owen A., et al.
Publicado: (2018)

A Cost-effectiveness Analysis of Brentuximab Vedotin in Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma
por: Hux, Margaret, et al.
Publicado: (2016)

Durable Response to Brentuximab Vedotin-Based Chemotherapy in Refractory Hodgkin Lymphoma with Central Nervous System (CNS) Involvement
por: Mociková, Heidi, et al.
Publicado: (2020)

Brentuximab vedotin for treatment of relapsed or refractory malignant lymphoma: results of a systematic review and meta-analysis of prospective studies
por: Chen, Runzhe, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_r29qlijdvm6erfg9ltcid632o0